A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Colorectal Cancer|Uveal Melanoma|Cutaneous Melanoma|Non-Small Cell Lung Cancer|Head and Neck Squamous Cell Carcinoma
Interventions: BIOLOGICAL: TBio-4101|DRUG: Pembrolizumab
Sponsor: Turnstone Biologics, Corp.